Lapatinib  ||| S:0 E:10 ||| NNP
for  ||| S:10 E:14 ||| IN
the  ||| S:14 E:18 ||| DT
treatment  ||| S:18 E:28 ||| NN
of  ||| S:28 E:31 ||| IN
HER2-overexpressing  ||| S:31 E:51 ||| CD
breast  ||| S:51 E:58 ||| NN
cancer  ||| S:58 E:65 ||| NN
This  ||| S:65 E:70 ||| DT
paper  ||| S:70 E:76 ||| NN
presents  ||| S:76 E:85 ||| VBZ
a  ||| S:85 E:87 ||| DT
summary  ||| S:87 E:95 ||| NN
of  ||| S:95 E:98 ||| IN
the  ||| S:98 E:102 ||| DT
evidence  ||| S:102 E:111 ||| NN
review  ||| S:111 E:118 ||| NN
group  ||| S:118 E:124 ||| NN
( ||| S:124 E:125 ||| -LRB-
ERG ||| S:125 E:128 ||| NNP
)  ||| S:128 E:130 ||| -RRB-
report  ||| S:130 E:137 ||| NN
into  ||| S:137 E:142 ||| IN
the  ||| S:142 E:146 ||| DT
clinical  ||| S:146 E:155 ||| JJ
effectiveness  ||| S:155 E:169 ||| NN
and  ||| S:169 E:173 ||| CC
cost-effectiveness  ||| S:173 E:192 ||| JJ
of  ||| S:192 E:195 ||| IN
lapatinib  ||| S:195 E:205 ||| NN
for  ||| S:205 E:209 ||| IN
the  ||| S:209 E:213 ||| DT
treatment  ||| S:213 E:223 ||| NN
of  ||| S:223 E:226 ||| IN
advanced  ||| S:226 E:235 ||| JJ
or  ||| S:235 E:238 ||| CC
metastatic  ||| S:238 E:249 ||| CD
HER2-overexpressing  ||| S:249 E:269 ||| CD
breast  ||| S:269 E:276 ||| NN
cancer  ||| S:276 E:283 ||| NN
based  ||| S:283 E:289 ||| VBN
upon  ||| S:289 E:294 ||| IN
a  ||| S:294 E:296 ||| DT
review  ||| S:296 E:303 ||| NN
of  ||| S:303 E:306 ||| IN
the  ||| S:306 E:310 ||| DT
manufacturer ||| S:310 E:322 ||| NN
's  ||| S:322 E:325 ||| POS
submission  ||| S:325 E:336 ||| NN
to  ||| S:336 E:339 ||| TO
the  ||| S:339 E:343 ||| DT
National  ||| S:343 E:352 ||| NNP
Institute  ||| S:352 E:362 ||| NNP
for  ||| S:362 E:366 ||| IN
Health  ||| S:366 E:373 ||| NNP
and  ||| S:373 E:377 ||| CC
Clinical  ||| S:377 E:386 ||| NNP
Excellence  ||| S:386 E:397 ||| NNP
( ||| S:397 E:398 ||| -LRB-
NICE ||| S:398 E:402 ||| NNP
)  ||| S:402 E:404 ||| -RRB-
as  ||| S:404 E:407 ||| IN
part  ||| S:407 E:412 ||| NN
of  ||| S:412 E:415 ||| IN
the  ||| S:415 E:419 ||| DT
single  ||| S:419 E:426 ||| JJ
technology  ||| S:426 E:437 ||| NN
appraisal  ||| S:437 E:447 ||| NN
( ||| S:447 E:448 ||| -LRB-
STA ||| S:448 E:451 ||| NNP
)  ||| S:451 E:453 ||| -RRB-
process ||| S:453 E:460 ||| NN
.  ||| S:460 E:462 ||| .
The  ||| S:462 E:466 ||| DT
scope  ||| S:466 E:472 ||| NN
included  ||| S:472 E:481 ||| VBD
women  ||| S:481 E:487 ||| NNS
with  ||| S:487 E:492 ||| IN
advanced ||| S:492 E:500 ||| JJ
,  ||| S:500 E:502 ||| ,
metastatic  ||| S:502 E:513 ||| NN
or  ||| S:513 E:516 ||| CC
recurrent  ||| S:516 E:526 ||| CD
HER2-overexpressing  ||| S:526 E:546 ||| CD
breast  ||| S:546 E:553 ||| NN
cancer  ||| S:553 E:560 ||| NN
who  ||| S:560 E:564 ||| WP
have  ||| S:564 E:569 ||| VBP
had  ||| S:569 E:573 ||| VBN
previous  ||| S:573 E:582 ||| JJ
therapy  ||| S:582 E:590 ||| NN
that  ||| S:590 E:595 ||| WDT
includes  ||| S:595 E:604 ||| VBZ
trastuzumab ||| S:604 E:615 ||| VBN
.  ||| S:615 E:617 ||| .
Outcomes  ||| S:617 E:626 ||| NNP
were  ||| S:626 E:631 ||| VBD
time  ||| S:631 E:636 ||| NN
to  ||| S:636 E:639 ||| TO
progression ||| S:639 E:650 ||| VB
,  ||| S:650 E:652 ||| ,
progression-free  ||| S:652 E:669 ||| JJ
survival ||| S:669 E:677 ||| NN
,  ||| S:677 E:679 ||| ,
response  ||| S:679 E:688 ||| NN
rates ||| S:688 E:693 ||| NNS
,  ||| S:693 E:695 ||| ,
overall  ||| S:695 E:703 ||| JJ
survival ||| S:703 E:711 ||| NN
,  ||| S:711 E:713 ||| ,
health-related  ||| S:713 E:728 ||| JJ
quality  ||| S:728 E:736 ||| NN
of  ||| S:736 E:739 ||| IN
life  ||| S:739 E:744 ||| NN
and  ||| S:744 E:748 ||| CC
adverse  ||| S:748 E:756 ||| JJ
effects ||| S:756 E:763 ||| NNS
.  ||| S:763 E:765 ||| .
The  ||| S:765 E:769 ||| DT
submission ||| S:769 E:779 ||| NN
's  ||| S:779 E:782 ||| POS
evidence  ||| S:782 E:791 ||| NN
came  ||| S:791 E:796 ||| VBD
from  ||| S:796 E:801 ||| IN
one  ||| S:801 E:805 ||| CD
randomised  ||| S:805 E:816 ||| NNS
controlled  ||| S:816 E:827 ||| VBN
trial  ||| S:827 E:833 ||| NN
( ||| S:833 E:834 ||| -LRB-
RCT ||| S:834 E:837 ||| NNP
)  ||| S:837 E:839 ||| -RRB-
of  ||| S:839 E:842 ||| IN
reasonable  ||| S:842 E:853 ||| JJ
methodological  ||| S:853 E:868 ||| JJ
quality ||| S:868 E:875 ||| NN
,  ||| S:875 E:877 ||| ,
although  ||| S:877 E:886 ||| IN
it  ||| S:886 E:889 ||| PRP
was  ||| S:889 E:893 ||| VBD
not  ||| S:893 E:897 ||| RB
powered  ||| S:897 E:905 ||| VBN
to  ||| S:905 E:908 ||| TO
detect  ||| S:908 E:915 ||| VB
a  ||| S:915 E:917 ||| DT
statistically  ||| S:917 E:931 ||| JJ
significant  ||| S:931 E:943 ||| JJ
difference  ||| S:943 E:954 ||| NN
in  ||| S:954 E:957 ||| IN
mean  ||| S:957 E:962 ||| JJ
overall  ||| S:962 E:970 ||| JJ
survival ||| S:970 E:978 ||| NN
.  ||| S:978 E:980 ||| .
Median  ||| S:980 E:987 ||| JJ
time  ||| S:987 E:992 ||| NN
to  ||| S:992 E:995 ||| TO
progression  ||| S:995 E:1007 ||| NNS
was  ||| S:1007 E:1011 ||| VBD
longer  ||| S:1011 E:1018 ||| RBR
in  ||| S:1018 E:1021 ||| IN
the  ||| S:1021 E:1025 ||| DT
lapatinib  ||| S:1025 E:1035 ||| NN
plus  ||| S:1035 E:1040 ||| CC
capecitabine  ||| S:1040 E:1053 ||| JJ
arm  ||| S:1053 E:1057 ||| NN
than  ||| S:1057 E:1062 ||| IN
in  ||| S:1062 E:1065 ||| IN
the  ||| S:1065 E:1069 ||| DT
capecitabine  ||| S:1069 E:1082 ||| JJ
monotherapy  ||| S:1082 E:1094 ||| JJ
arm  ||| S:1094 E:1098 ||| NN
{ ||| S:1098 E:1099 ||| -LRB-
27.1  ||| S:1099 E:1104 ||| CD
[ ||| S:1104 E:1105 ||| -LRB-
95 ||| S:1105 E:1107 ||| CD
%  ||| S:1107 E:1109 ||| NN
confidence  ||| S:1109 E:1120 ||| NN
interval  ||| S:1120 E:1129 ||| NNS
( ||| S:1129 E:1130 ||| -LRB-
CI ||| S:1130 E:1132 ||| NNP
)  ||| S:1132 E:1134 ||| -RRB-
17.4  ||| S:1134 E:1139 ||| CD
to  ||| S:1139 E:1142 ||| TO
49.4 ||| S:1142 E:1146 ||| CD
]  ||| S:1146 E:1148 ||| -RRB-
versus  ||| S:1148 E:1155 ||| FW
18.6  ||| S:1155 E:1160 ||| FW
[ ||| S:1160 E:1161 ||| -LRB-
95 ||| S:1161 E:1163 ||| CD
%  ||| S:1163 E:1165 ||| NN
CI  ||| S:1165 E:1168 ||| NNP
9.1  ||| S:1168 E:1172 ||| CD
to  ||| S:1172 E:1175 ||| TO
36.9 ||| S:1175 E:1179 ||| CD
]  ||| S:1179 E:1181 ||| -RRB-
weeks ||| S:1181 E:1186 ||| NNS
;  ||| S:1186 E:1188 ||| :
hazard  ||| S:1188 E:1195 ||| JJ
ratio  ||| S:1195 E:1201 ||| NN
0.57  ||| S:1201 E:1206 ||| CD
[ ||| S:1206 E:1207 ||| -LRB-
95 ||| S:1207 E:1209 ||| CD
%  ||| S:1209 E:1211 ||| NN
CI  ||| S:1211 E:1214 ||| NNP
0.43  ||| S:1214 E:1219 ||| CD
to  ||| S:1219 E:1222 ||| TO
0.77 ||| S:1222 E:1226 ||| CD
;  ||| S:1226 E:1228 ||| :
p  ||| S:1228 E:1230 ||| CD
=  ||| S:1230 E:1232 ||| SYM
0.00013 ||| S:1232 E:1239 ||| CD
] ||| S:1239 E:1240 ||| CD
} ||| S:1240 E:1241 ||| -RRB-
.  ||| S:1241 E:1243 ||| .
Median  ||| S:1243 E:1250 ||| JJ
overall  ||| S:1250 E:1258 ||| JJ
survival  ||| S:1258 E:1267 ||| NN
was  ||| S:1267 E:1271 ||| VBD
very  ||| S:1271 E:1276 ||| RB
similar  ||| S:1276 E:1284 ||| JJ
between  ||| S:1284 E:1292 ||| IN
the  ||| S:1292 E:1296 ||| DT
groups  ||| S:1296 E:1303 ||| NNS
[ ||| S:1303 E:1304 ||| -LRB-
67.7  ||| S:1304 E:1309 ||| NNP
( ||| S:1309 E:1310 ||| -LRB-
95 ||| S:1310 E:1312 ||| CD
%  ||| S:1312 E:1314 ||| NN
CI  ||| S:1314 E:1317 ||| NNP
58.9  ||| S:1317 E:1322 ||| CD
to  ||| S:1322 E:1325 ||| TO
91.6 ||| S:1325 E:1329 ||| CD
)  ||| S:1329 E:1331 ||| -RRB-
versus  ||| S:1331 E:1338 ||| FW
66.6  ||| S:1338 E:1343 ||| FW
( ||| S:1343 E:1344 ||| -LRB-
95 ||| S:1344 E:1346 ||| CD
%  ||| S:1346 E:1348 ||| NN
CI  ||| S:1348 E:1351 ||| NNP
49.1  ||| S:1351 E:1356 ||| CD
to  ||| S:1356 E:1359 ||| TO
75.0 ||| S:1359 E:1363 ||| CD
)  ||| S:1363 E:1365 ||| -RRB-
weeks ||| S:1365 E:1370 ||| NNS
;  ||| S:1370 E:1372 ||| :
hazard  ||| S:1372 E:1379 ||| FW
ratio  ||| S:1379 E:1385 ||| FW
0.78  ||| S:1385 E:1390 ||| FW
( ||| S:1390 E:1391 ||| -LRB-
95 ||| S:1391 E:1393 ||| CD
%  ||| S:1393 E:1395 ||| NN
CI  ||| S:1395 E:1398 ||| NNP
0.55  ||| S:1398 E:1403 ||| CD
to  ||| S:1403 E:1406 ||| TO
1.12 ||| S:1406 E:1410 ||| CD
;  ||| S:1410 E:1412 ||| :
p  ||| S:1412 E:1414 ||| CD
=  ||| S:1414 E:1416 ||| SYM
0.177 ||| S:1416 E:1421 ||| CD
) ||| S:1421 E:1422 ||| -RRB-
] ||| S:1422 E:1423 ||| -RRB-
.  ||| S:1423 E:1425 ||| .
Median  ||| S:1425 E:1432 ||| JJ
progression-free  ||| S:1432 E:1449 ||| JJ
survival  ||| S:1449 E:1458 ||| NN
was  ||| S:1458 E:1462 ||| VBD
statistically  ||| S:1462 E:1476 ||| RB
significantly  ||| S:1476 E:1490 ||| RB
longer  ||| S:1490 E:1497 ||| RBR
in  ||| S:1497 E:1500 ||| IN
the  ||| S:1500 E:1504 ||| DT
lapatinib  ||| S:1504 E:1514 ||| NN
plus  ||| S:1514 E:1519 ||| CC
capecitabine  ||| S:1519 E:1532 ||| JJ
group  ||| S:1532 E:1538 ||| NN
than  ||| S:1538 E:1543 ||| IN
in  ||| S:1543 E:1546 ||| IN
the  ||| S:1546 E:1550 ||| DT
capecitabine  ||| S:1550 E:1563 ||| JJ
monotherapy  ||| S:1563 E:1575 ||| JJ
group  ||| S:1575 E:1581 ||| NN
[ ||| S:1581 E:1582 ||| -LRB-
27.1  ||| S:1582 E:1587 ||| CD
( ||| S:1587 E:1588 ||| -LRB-
95 ||| S:1588 E:1590 ||| CD
%  ||| S:1590 E:1592 ||| NN
CI  ||| S:1592 E:1595 ||| NNP
24.1  ||| S:1595 E:1600 ||| CD
to  ||| S:1600 E:1603 ||| TO
36.9 ||| S:1603 E:1607 ||| CD
)  ||| S:1607 E:1609 ||| -RRB-
versus  ||| S:1609 E:1616 ||| FW
17.6  ||| S:1616 E:1621 ||| FW
( ||| S:1621 E:1622 ||| -LRB-
95 ||| S:1622 E:1624 ||| CD
%  ||| S:1624 E:1626 ||| NN
CI  ||| S:1626 E:1629 ||| NNP
13.3  ||| S:1629 E:1634 ||| CD
to  ||| S:1634 E:1637 ||| TO
20.1 ||| S:1637 E:1641 ||| CD
)  ||| S:1641 E:1643 ||| -RRB-
weeks ||| S:1643 E:1648 ||| NNS
;  ||| S:1648 E:1650 ||| :
hazard  ||| S:1650 E:1657 ||| JJ
ratio  ||| S:1657 E:1663 ||| NN
0.55  ||| S:1663 E:1668 ||| CD
( ||| S:1668 E:1669 ||| -LRB-
95 ||| S:1669 E:1671 ||| CD
%  ||| S:1671 E:1673 ||| NN
CI  ||| S:1673 E:1676 ||| NNP
0.41  ||| S:1676 E:1681 ||| NNP
to  ||| S:1681 E:1684 ||| TO
0.74 ||| S:1684 E:1688 ||| CD
) ||| S:1688 E:1689 ||| -RRB-
;  ||| S:1689 E:1691 ||| :
p  ||| S:1691 E:1693 ||| CD
=  ||| S:1693 E:1695 ||| SYM
0.000033 ||| S:1695 E:1703 ||| CD
] ||| S:1703 E:1704 ||| -RRB-
.  ||| S:1704 E:1706 ||| .
The  ||| S:1706 E:1710 ||| DT
manufacturer ||| S:1710 E:1722 ||| NN
's  ||| S:1722 E:1725 ||| POS
economic  ||| S:1725 E:1734 ||| JJ
model  ||| S:1734 E:1740 ||| NN
to  ||| S:1740 E:1743 ||| TO
estimate  ||| S:1743 E:1752 ||| VB
progression-free  ||| S:1752 E:1769 ||| JJ
and  ||| S:1769 E:1773 ||| CC
overall  ||| S:1773 E:1781 ||| JJ
survival  ||| S:1781 E:1790 ||| NN
for  ||| S:1790 E:1794 ||| IN
patients  ||| S:1794 E:1803 ||| NNS
with  ||| S:1803 E:1808 ||| IN
HER2-positive  ||| S:1808 E:1822 ||| NNP
advanced ||| S:1822 E:1830 ||| VBD
/ ||| S:1830 E:1831 ||| CD
metastatic  ||| S:1831 E:1842 ||| JJ
breast  ||| S:1842 E:1849 ||| NN
cancer  ||| S:1849 E:1856 ||| NN
who  ||| S:1856 E:1860 ||| WP
had  ||| S:1860 E:1864 ||| VBD
relapsed  ||| S:1864 E:1873 ||| VBN
following  ||| S:1873 E:1883 ||| VBG
treatment  ||| S:1883 E:1893 ||| NN
with  ||| S:1893 E:1898 ||| IN
an  ||| S:1898 E:1901 ||| DT
anthracycline ||| S:1901 E:1914 ||| NN
,  ||| S:1914 E:1916 ||| ,
a  ||| S:1916 E:1918 ||| DT
taxane  ||| S:1918 E:1925 ||| NN
and  ||| S:1925 E:1929 ||| CC
trastuzumab  ||| S:1929 E:1941 ||| NNS
was  ||| S:1941 E:1945 ||| VBD
appropriate  ||| S:1945 E:1957 ||| JJ
for  ||| S:1957 E:1961 ||| IN
the  ||| S:1961 E:1965 ||| DT
disease  ||| S:1965 E:1973 ||| NN
area ||| S:1973 E:1977 ||| NN
.  ||| S:1977 E:1979 ||| .
The  ||| S:1979 E:1983 ||| DT
base-case  ||| S:1983 E:1993 ||| JJ
incremental  ||| S:1993 E:2005 ||| JJ
cost-effectiveness  ||| S:2005 E:2024 ||| JJ
ratios  ||| S:2024 E:2031 ||| NNS
( ||| S:2031 E:2032 ||| -LRB-
ICERs ||| S:2032 E:2037 ||| NNP
)  ||| S:2037 E:2039 ||| -RRB-
for  ||| S:2039 E:2043 ||| IN
lapatinib  ||| S:2043 E:2053 ||| NN
plus  ||| S:2053 E:2058 ||| CC
capecitabine  ||| S:2058 E:2071 ||| VB
compared  ||| S:2071 E:2080 ||| VBN
with  ||| S:2080 E:2085 ||| IN
capecitabine  ||| S:2085 E:2098 ||| JJ
monotherapy  ||| S:2098 E:2110 ||| NN
or  ||| S:2110 E:2113 ||| CC
vinorelbine  ||| S:2113 E:2125 ||| JJ
monotherapy  ||| S:2125 E:2137 ||| NN
were  ||| S:2137 E:2142 ||| VBD
higher  ||| S:2142 E:2149 ||| JJR
than  ||| S:2149 E:2154 ||| IN
would  ||| S:2154 E:2160 ||| MD
conventionally  ||| S:2160 E:2175 ||| RB
be  ||| S:2175 E:2178 ||| VB
considered  ||| S:2178 E:2189 ||| VBN
cost-effective ||| S:2189 E:2203 ||| JJ
.  ||| S:2203 E:2205 ||| .
When  ||| S:2205 E:2210 ||| WRB
compared  ||| S:2210 E:2219 ||| VBN
with  ||| S:2219 E:2224 ||| IN
trastuzumab-containing  ||| S:2224 E:2247 ||| JJ
regimes ||| S:2247 E:2254 ||| NN
,  ||| S:2254 E:2256 ||| ,
lapatinib  ||| S:2256 E:2266 ||| NN
plus  ||| S:2266 E:2271 ||| CC
capecitabine  ||| S:2271 E:2284 ||| VB
dominated ||| S:2284 E:2293 ||| VBN
.  ||| S:2293 E:2295 ||| .
In  ||| S:2295 E:2298 ||| IN
sensitivity  ||| S:2298 E:2310 ||| JJ
analyses  ||| S:2310 E:2319 ||| NNS
the  ||| S:2319 E:2323 ||| DT
ICER  ||| S:2323 E:2328 ||| NNP
for  ||| S:2328 E:2332 ||| IN
lapatinib  ||| S:2332 E:2342 ||| NN
plus  ||| S:2342 E:2347 ||| CC
capecitabine  ||| S:2347 E:2360 ||| VB
compared  ||| S:2360 E:2369 ||| VBN
with  ||| S:2369 E:2374 ||| IN
capecitabine  ||| S:2374 E:2387 ||| JJ
monotherapy  ||| S:2387 E:2399 ||| NN
or  ||| S:2399 E:2402 ||| CC
vinorelbine  ||| S:2402 E:2414 ||| JJ
monotherapy  ||| S:2414 E:2426 ||| NN
was  ||| S:2426 E:2430 ||| VBD
robust  ||| S:2430 E:2437 ||| JJ
to  ||| S:2437 E:2440 ||| TO
variation  ||| S:2440 E:2450 ||| VB
in  ||| S:2450 E:2453 ||| IN
assumptions ||| S:2453 E:2464 ||| NNS
.  ||| S:2464 E:2466 ||| .
In  ||| S:2466 E:2469 ||| IN
all  ||| S:2469 E:2473 ||| DT
sensitivity  ||| S:2473 E:2485 ||| NN
analyses  ||| S:2485 E:2494 ||| NNS
the  ||| S:2494 E:2498 ||| DT
ICERs  ||| S:2498 E:2504 ||| NN
remained  ||| S:2504 E:2513 ||| VBD
higher  ||| S:2513 E:2520 ||| JJR
than  ||| S:2520 E:2525 ||| IN
would  ||| S:2525 E:2531 ||| MD
conventionally  ||| S:2531 E:2546 ||| RB
be  ||| S:2546 E:2549 ||| VB
considered  ||| S:2549 E:2560 ||| VBN
cost-effective ||| S:2560 E:2574 ||| JJ
.  ||| S:2574 E:2576 ||| .
ICERs  ||| S:2576 E:2582 ||| JJ
for  ||| S:2582 E:2586 ||| IN
trastuzumab-containing  ||| S:2586 E:2609 ||| JJ
regimes  ||| S:2609 E:2617 ||| NN
were  ||| S:2617 E:2622 ||| VBD
particularly  ||| S:2622 E:2635 ||| RB
sensitive  ||| S:2635 E:2645 ||| JJ
to  ||| S:2645 E:2648 ||| TO
assumptions  ||| S:2648 E:2660 ||| NNS
over  ||| S:2660 E:2665 ||| IN
the  ||| S:2665 E:2669 ||| DT
frequency  ||| S:2669 E:2679 ||| NN
of  ||| S:2679 E:2682 ||| IN
treatment ||| S:2682 E:2691 ||| NN
,  ||| S:2691 E:2693 ||| ,
which  ||| S:2693 E:2699 ||| WDT
had  ||| S:2699 E:2703 ||| VBD
a  ||| S:2703 E:2705 ||| DT
large  ||| S:2705 E:2711 ||| JJ
effect  ||| S:2711 E:2718 ||| NN
on  ||| S:2718 E:2721 ||| IN
the  ||| S:2721 E:2725 ||| DT
cost-effectiveness  ||| S:2725 E:2744 ||| JJ
of  ||| S:2744 E:2747 ||| IN
lapatinib  ||| S:2747 E:2757 ||| NN
plus  ||| S:2757 E:2762 ||| CC
capecitabine ||| S:2762 E:2774 ||| NN
.  ||| S:2774 E:2776 ||| .
In  ||| S:2776 E:2779 ||| IN
conclusion ||| S:2779 E:2789 ||| NN
,  ||| S:2789 E:2791 ||| ,
there  ||| S:2791 E:2797 ||| EX
was  ||| S:2797 E:2801 ||| VBD
a  ||| S:2801 E:2803 ||| DT
general  ||| S:2803 E:2811 ||| JJ
lack  ||| S:2811 E:2816 ||| NN
of  ||| S:2816 E:2819 ||| IN
evidence  ||| S:2819 E:2828 ||| NN
on  ||| S:2828 E:2831 ||| IN
the  ||| S:2831 E:2835 ||| DT
effectiveness  ||| S:2835 E:2849 ||| NN
of  ||| S:2849 E:2852 ||| IN
comparators  ||| S:2852 E:2864 ||| NN
included  ||| S:2864 E:2873 ||| VBD
in  ||| S:2873 E:2876 ||| IN
the  ||| S:2876 E:2880 ||| DT
model  ||| S:2880 E:2886 ||| NN
and  ||| S:2886 E:2890 ||| CC
on  ||| S:2890 E:2893 ||| IN
key  ||| S:2893 E:2897 ||| JJ
parameters  ||| S:2897 E:2908 ||| JJ
such  ||| S:2908 E:2913 ||| JJ
as  ||| S:2913 E:2916 ||| IN
dose  ||| S:2916 E:2921 ||| NN
adjustments  ||| S:2921 E:2933 ||| NNS
and  ||| S:2933 E:2937 ||| CC
the  ||| S:2937 E:2941 ||| DT
model  ||| S:2941 E:2947 ||| NN
outputs  ||| S:2947 E:2955 ||| NNS
need  ||| S:2955 E:2960 ||| VBP
to  ||| S:2960 E:2963 ||| TO
be  ||| S:2963 E:2966 ||| VB
interpreted  ||| S:2966 E:2978 ||| VBN
in  ||| S:2978 E:2981 ||| IN
the  ||| S:2981 E:2985 ||| DT
light  ||| S:2985 E:2991 ||| NN
of  ||| S:2991 E:2994 ||| IN
this  ||| S:2994 E:2999 ||| DT
uncertainty ||| S:2999 E:3010 ||| NN
.  ||| S:3010 E:3012 ||| .
At  ||| S:3012 E:3015 ||| IN
the  ||| S:3015 E:3019 ||| DT
time  ||| S:3019 E:3024 ||| NN
of  ||| S:3024 E:3027 ||| IN
writing ||| S:3027 E:3034 ||| NN
,  ||| S:3034 E:3036 ||| ,
NICE  ||| S:3036 E:3041 ||| NNP
were  ||| S:3041 E:3046 ||| VBD
still  ||| S:3046 E:3052 ||| RB
considering  ||| S:3052 E:3064 ||| VBG
the  ||| S:3064 E:3068 ||| DT
available  ||| S:3068 E:3078 ||| JJ
evidence  ||| S:3078 E:3087 ||| NN
for  ||| S:3087 E:3091 ||| IN
this  ||| S:3091 E:3096 ||| DT
appraisal ||| S:3096 E:3105 ||| NN
.  ||| S:3105 E:3107 ||| .
